September 30, 2020
European regulators have approved Equidacent, a biosimilar version of Roche’s anticancer agent Avastin (bevacizumab) developed by Centus Biotherapeutics, a joint venture of Fujifilm Kyowa Kirin Biologics and AstraZeneca. Centus said on September 29 that Equidacent was granted approval by the...read more